Latest News for: ocular

Edit

Annual Report (Form ARS) (Ocular Therapeutix Inc)

Public Technologies 01 May 2026
). The text version of this document is not available ... Ocular Therapeutix Inc.
Edit

Additional Proxy Soliciting Materials (Form DEFA14A) (Ocular Therapeutix Inc)

Public Technologies 01 May 2026
Ocular Therapeutix, Inc ... OCULAR THERAPEUTIX, INC. 14 CROSBY DRIVE, 3RD FLOOR BEDFORD, MA 01730 OCULAR THERAPEUTIX, INC ... www.virtualshareholdermeeting.com/OCUL2026 You invested in OCULAR THERAPEUTIX, INC ... Ocular Therapeutix Inc.
Edit

Proxy Statement (Form DEF 14A) (Ocular Therapeutix Inc)

Public Technologies 01 May 2026
Ocular Therapeutix, Inc ... Dear Fellow Ocular Therapeutix Stockholders. ... In 2025, Ocular's achievements included ... On behalf of the entire Ocular Therapeutix board, I would like to express our appreciation for your continued investment in our company.
Edit

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Nasdaq Globe Newswire 29 Apr 2026
SOL-X long-term extension trial in wet AMD enrolled the first subject in April 2026 who had successfully completed the two-year SOL-1 trial ... .
Edit

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

Nasdaq Globe Newswire 28 Apr 2026
BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc.
Edit

Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences

Nasdaq Globe Newswire 27 Apr 2026
BEDFORD, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ocular ...
Edit

With GLP-1 generics making debut, doctors warn of ocular risks

The Times of India 25 Apr 2026
Comments. +Text SizeSmallMediumLarge. .
Edit

Innovative ocular solutions: Improving lives through advanced therapies (Fortrea Holdings Inc)

Public Technologies 23 Apr 2026
Our extensive experience spans multiple indications, from front and back-of-the-eye conditions to rare ocular diseases, cell and gene therapies, pediatrics and ophthalmic devices and [...].
Edit

Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Nasdaq Globe Newswire 22 Apr 2026
Ocular’s Investor Day will take place in New York City, ...
Edit

How Nanoparticle Technologies Aid Ocular Drug Delivery (Ascendia Pharmaceuticals Inc)

Public Technologies 20 Apr 2026
Ocular drug delivery has been a subject of continued interest in development of innovative drugs due, in part, to poor bioavailability (ca ... Overcoming Ocular Barriers ... An ocular dose is typically 5-15 mL (with few exceptions) for commercial eye drops.
Edit

EssilorLuxottica partners with TFOS to advance global standards in ocular surface health (EssilorLuxottica SA)

Public Technologies 17 Apr 2026
) The Company has announced a strategic partnership with the Tear Film & Ocular Surface Society (TFOS), an international non-profit organization dedicated ...
Edit

Rhesus macaques with an OPA1 mutation demonstrate features of autosomal dominant optic atrophy

PNAS 15 Apr 2026
One such condition is autosomal dominant optic atrophy (ADOA), an ... .
Edit

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nasdaq Globe Newswire 14 Apr 2026
The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s ...
Edit

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of ...

Nasdaq Globe Newswire 13 Apr 2026
New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control ... .
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Ocular Therapeutix Inc)

Public Technologies 13 Apr 2026
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue ... Washington, D.C ... OCULAR THERAPEUTIX, INC [OCUL] 5 ... C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE 3 ... C/O OCULAR THERAPEUTIX, INC ... Ocular Therapeutix Inc.

Article Search

tools
×
×
×
×